Inactive Instrument

Analyst Reco. TURG POIN

Equities

TPTX

US90041T1088

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

Guggenheim Downgrades Turning Point Therapeutics to Neutral From Buy, Adjusts Price Target to $76 From $72	22-06-13	MT
SVB Securities Downgrades Turning Point Therapeutics to Market Perform From Outperform, Adjusts Price Target to $76 From $101	22-06-13	MT
Oppenheimer Downgrades Turning Point Therapeutics to Market Perform From Outperform	22-06-06	MT
Cowen Downgrades Turning Point Therapeutics to Market Perform from Outperform	22-06-06	MT
HC Wainwright Cuts Turning Point Therapeutics to Neutral From Buy, Price Target to $76 From $161	22-06-06	MT
Wells Fargo Downgrades Turning Point Therapeutics to Equalweight From Overweight, Adjusts Price Target to $76 From $85	22-06-06	MT
US Stocks Finish Holiday-Shortened Week Lower as May Unemployment Rate Holds Steady	22-06-03	MT
Equities Fall Midday After May Unemployment Rate Remains Unchanged	22-06-03	MT
Midday Report: US Equity Indices Fall After May Unemployment Rate Remains Unchanged	22-06-03	MT
Wedbush Downgrades Turning Point Therapeutics to Neutral From Outperform, Adjusts Price Target to $76 From $61 on Bristol-Myers Squibb Offer	22-06-03	MT
Goldman Sachs Adjusts Price Target for Turning Point Therapeutics to $116 From $143, Keeps Buy Rating	22-05-24	MT
BofA Securities Starts Turning Point Therapeutics at Buy With $58 Price Target	22-05-20	MT
SVB Securities Adjusts Turning Point Therapeutics' Price Target to $101 from $107, Keeps Outperform Rating	22-05-11	MT
Wedbush Lowers Turning Point Therapeutics' Price Target to $61 from $93, Keeps Outperform Rating	22-05-11	MT
Wedbush Adjusts Price Target on Turning Point Therapeutics to $93 From $101, Keeps Outperform Rating	22-04-13	MT
Guggenheim Adjusts Price Target on Turning Point Therapeutics to $72 From $82, Reiterates Buy Rating	22-03-25	MT
HC Wainwright Adjusts Turning Point Therapeutics' Price Target to $161 From $162, Keeps Buy Rating	22-03-22	MT
Wedbush Adjusts Price Target on Turning Point Therapeutics to $101 From $125, Citing Cost of Capital, Product Launch Adjustments; Outperform Rating Kept	22-03-01	MT
Wells Fargo Adjusts Turning Point Therapeutics' Price Target to $85 from $120, Maintains Overweight Rating	22-02-10	MT
Oppenheimer Adjusts Turning Point Therapeutics' Price Target to $105 From $115, Maintains Outperform Rating	22-01-21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. TURG POIN

Equities

TPTX

US90041T1088

Analyst Reco.

Filters